Enrolling! Contact a study coordinator with questions
Merck Sharpe & Dohme's Pneumoccocal Vaccine
Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Novel Pneumococcal Vaccine in Children
Stage 1: Healthy toddlers 12 through 15 months of age who have previously completed a 3-dose routine infant series with PCV20
For more info: https://clinicaltrials.gov/study/NCT07300267
Primary Coordinator: KaTia Whindleton (KaTia@proc211.com)
Pfizer Rimegepant Migraine Treatment
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of Rimegepant for the treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
For more info: https://clinicaltrials.gov/study/NCT04649242
Primary Coordinator: Uyen Tran (Uyen@proc211.com)
Pfizer Long-term Migraine Treatment
Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of Rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to <18 years of age
For more info: https://clinicaltrials.gov/study/NCT04743141?id=C4951003&rank=1
Primary Coordinator: Uyen Tran (Uyen@proc211.com)
Vaxcyte 31-Valent Pneumococcal Conjugate Vaccine
Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12–15 Months of Age Concomitantly with Routine Pediatric Vaccines
For more info:
Primary Coordinator: Cathy Hansa (Catherine@proc211.com)
Enrolling soon!
Pfizer 4th Gen Pneumoccocal Vaccine
Pfizer 4th Gen Pneumoccocal Vaccine
4th Generation Pneumococcal Vaccine
Children and adolescents ≥ 15 Months to < 18 Years of Age
Primary Coordinator:
KaTia Whindleton (KaTia@proc211.com)
Pfizer 4th Gen Pneumoccocal Vaccine
Pfizer 4th Gen Pneumoccocal Vaccine
4th Generation Pneumococcal Vaccine
Infants 2 months of age (≥42 to ≤98 days)
Primary Coordinator: Cheryll Caalim (Cheryll@proc211.com)
Merck Sharpe & Dohme Pneumoccocal Vaccine
Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Novel Pneumococcal Vaccine in Children
Stage 2: healthy infants approximately 2 months of age (42 days to 90 days)
For more info: https://clinicaltrials.gov/study/NCT07300267
Primary Coordinator: KaTia Whindleton (KaTia@proc211.com)
Abbvie Ubrogepant Migraine Medication
Bausch Health Plecanatide Functional Constipation Medication
Ubrogepant for acute treatment of migraines (Randomized, double-blind, placebo-controlled)
Children and adolescents Ages 6 < 18 years with migraine with or without aura
Primary Coordinator: Uyen Tran (Uyen@proc211.com)
Abbvie Ubrogepant Migraine Medication
Bausch Health Plecanatide Functional Constipation Medication
Bausch Health Plecanatide Functional Constipation Medication
Ubrogepant for acute treatment of migraines (Open-label, extension study)
Children and adolescents Ages 6 < 18 years with migraine with or without aura
Primary Coordinator: Uyen Tran (Uyen@proc211.com)
Bausch Health Plecanatide Functional Constipation Medication
Bausch Health Plecanatide Functional Constipation Medication
Bausch Health Plecanatide Functional Constipation Medication
Plecanatide (Trulance)
(Randomized, double-blind, placebo-controlled)
Children and adolescents 6 < 18 years with functional constipation
Primary Coordinator: Cathy Hansa (Catherine@proc211.com)
Studies Currently in Follow-Up
Vaxcyte 31-Valent Pneumococcal Conjugate Vaccine
Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12–15 Months of Age Concomitantly with Routine Pediatric Vaccines
Primary Coordinator: Cathy Hansa (Catherine@proc211.com)
For more info: